Company Profile
Capricor Therapeutics Stock Price, News & Analysis
- Ticker:
- CAPR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.18 USD (+6.36%)
Close
Last updated: August 6, 2026
1.58B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CAPR closed up 6.36% at $4.18. No new same-company headline was identified in the current news window.
Company overview
Cell Therapy for Duchenne Muscular Dystrophy
Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.
Deramiocel
The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling.
HOPE-3 Evidence
The Phase 3 HOPE-3 study met its primary upper-limb function endpoint and all type I error-controlled secondary endpoints.
Future catalysts
The FDA PDUFA action date for the deramiocel BLA is August 22, 2026.
FDA labeling discussions are expected during the active BLA review.
Recent news
- 01
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
Source: Capricor Therapeutics
- 02
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Source: Capricor Therapeutics
- 03
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
Source: Capricor Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Capricor Therapeutics (CAPR)?
Capricor Therapeutics (CAPR) most recently closed at 4.18 USD, a +6.36% move versus the previous session.
What is the market cap of Capricor Therapeutics (CAPR)?
Capricor Therapeutics currently has a market capitalization of 1.58B USD on BioPharmSignal.
What does Capricor Therapeutics do?
Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The Phase 3 HOPE-3 study...
On which exchange is CAPR stock listed?
Capricor Therapeutics (CAPR) is associated with NASDAQ, United States, Biopharma.
What is HOPE-3?
HOPE-3 Evidence The Phase 3 HOPE-3 study met its primary upper-limb function endpoint and all type I error-controlled secondary endpoints.
Which conditions is Capricor Therapeutics targeting with HOPE-3?
Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The Phase 3 HOPE-3 study...
How does Capricor Therapeutics describe recent progress with HOPE-3?
The FDA PDUFA action date for the deramiocel BLA is August 22, 2026. FDA labeling discussions are expected during the active BLA review.
What is Cell?
Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.